Update: Method(3_method.md)のアウトライン・メモを拡充 ...

確定方針、Dataset、前処理（画像・臨床変数・プラーク面積特徴）、
KSCNet、比較手法、評価プロトコル、実装詳細、未解決事項を追記した。

Co-Authored-By: Claude Sonnet 5.5 <noreply@anthropic.com>

Update: Introductionを推敲し英訳に反映、Related Workの記述を調整 ...

複合基準の言い換え、課題文の削除、AMIの初出展開を反映
sections/1_introduction.texを日本語ドラフトに合わせて更新

Add Japanese draft of Related Work section ...

Three paragraphs covering: manual attenuated-plaque scoring via IVUS
(wu2011), deep-learning-based IVUS segmentation (nishi2021), and the
existing landscape of clinical/angiographic no-reflow prediction
models that don't use IVUS (li2025) — motivating this manuscript's
integration of IVUS imaging with clinical/lesion information.

Co-Authored-By: Claude Sonnet 5 <noreply@anthropic.com>

Note systemic side effects of prophylactic intracoronary vasodilators ...

Add Rezkalla et al. 2017 (JACC: Cardiovascular Interventions) as a
verified citation for the drawback, in both the Japanese draft and the
English Introduction section.

Co-Authored-By: Claude Sonnet 5 <noreply@anthropic.com>

Add drafting pipeline subagents and Method section Japanese draft ...

Adds the ja-drafter/fact-checker/content-reviewer/en-translator agent
definitions backing the section-drafting workflow, and the first
Japanese draft of the Method section.

Co-Authored-By: Claude Sonnet 5 <noreply@anthropic.com>

Refine Introduction wording and add two more verified citations ...

- Add wang2026 (USCNet) and hibi2013 (IVUS history review) to
  references.bib after reading the full PDFs; cite them for KSCNet's
  originating kidney-stone-classification architecture and for the
  claim that IVUS can visualize vessel wall/plaque condition,
  respectively.
- Drop "microvascular spasm" as a contributing factor from the
  no-reflow definition, trim an editorializing clause after the
  attenuated-plaque finding, and rephrase the IVUS-focus sentence as
  the paper's own rationale rather than a general background claim.
- Remove the unsupported vasodilator-treatment-limitations sentence
  and the citation-needed marker on preventive-measures (distal
  protection devices/prophylactic vasodilators), per review: none of
  the added source papers support the former, and the latter is
  standard clinical practice not requiring a citation.
- Generalize the poor-prognosis sentence (previously citing specific,
  unsupported outcomes) to a claim not requiring a citation.

Co-Authored-By: Claude Sonnet 5 <noreply@anthropic.com>

Wire up references.bib and verify citations against source PDFs ...

- Add citations/ folder holding the cited papers' PDFs (babapoor2022,
  wu2011, nishi2021), documented in CLAUDE.md so cite keys can be
  filled in/verified directly from the source paper instead of guessed.
- Fill in references.bib entries for all three keys with real
  bibliographic data, and drop a stray "@TODO" in the header comment
  that was making bibtex misparse the file as a malformed entry.
- Switch main.tex from the template's placeholder internal
  bibliography to \bibliography{references}, so citations actually
  resolve (previously rendered as undefined/"?").
- Correct the Introduction's babapoor2022/wu2011 citation claims after
  reading the full papers: babapoor2022 reports separate no-reflow
  (17.1%) and slow-flow (12.9%) rates in a single-center primary-PCI
  cohort, not a general "10-20% of PCI patients" figure; wu2011's
  finding is specific to AMI patients and a composite no-reflow/
  slow-flow (TIMI <=2) endpoint, and only the amount (not presence) of
  attenuated plaque differed significantly.

Co-Authored-By: Claude Sonnet 5 <noreply@anthropic.com>

Draft Introduction via ja-drafter/review/translate pipeline ...

Writes sections/1_introduction.tex through the documented workflow:
Japanese draft (drafts/ja/1_introduction.md), fact-check + content
review against the Notion source of truth, then English translation.
Centers the section on the proposed KSCNet architecture; open claims
without a source yet are left as inline [citation needed] markers.
Also documents the pipeline itself in CLAUDE.md.

Co-Authored-By: Claude Sonnet 5 <noreply@anthropic.com>